Panel features
CLIA-validated, ultra-sensitive blood test for the detection of CDKN2A, EGFR, ERBB2, FGFR3, HRAS, KRAS, NOTCH1, PIK3CA, PTEN, and TP53. This panel detects as few as 8 mutant molecules in a background of 20,000 wild-type molecules (0.04% mutant allele frequency).
GENE | GENE REGIONS COVERED (AMINO ACIDS) | CLINICAL RELEVANCE |
---|---|---|
CDKN2A | 51-61, 80-91, 96-124, 143-152 |
Putative therapeutic indication Marker of poor prognosis |
EGFR | 283-296, 463-486, 706-725, 856-873 | Therapeutic indication |
ERBB2 | 303-315 | |
FGFR3 | 248-269, 370-392 | Putative therapeutic indication |
HRAS | 9-19, 55-67, 110-123, 144-150 |
Putative therapeutic indication Marker of poor prognosis |
KRAS | 5-26, 141-148, 156-174 |
Predictive marker for anti-EGFR therapy Putative therapeutic marker |
NOTCH1 | 184-209, 290-315, 440-468, 562-582, 1836-1862, 1979-1997 | Putative therapeutic indication |
PICK3CA | 72-93, 108-117, 330-352, 354-371, 418-421, 440-462, 538-553, 597-614, 714-728, 970-978, 1001-1025, 1040-1056 | Putative therapeutic indication |
PTEN | 6-26, 87-104, 117-136, 229-247, 329-342 | Putative therapeutic indication |
TP53 | 10-24, 26-32, 49-77, 99-125, 126-141, 151-179, 192-219, 233-260, 262-285, 297-306, 308-331, 332-360, 368-383 | Truncal mutations important for monitoring |